<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296790</url>
  </required_header>
  <id_info>
    <org_study_id>PM_L_0167</org_study_id>
    <nct_id>NCT00296790</nct_id>
  </id_info>
  <brief_title>Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      A comparison of Zolpidem Tartrate Extended-Release (Ambien CR)vs. Placebo in the Treatment of&#xD;
      Insomnia Associated with Generalized Anxiety Disorder (GAD) when Used Concomitantly with&#xD;
      Escitalopram (Lexapro - antidepressant).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date>February 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate safety and hypnotic efficacy of zolpidem tartrate extended release vs. placebo in treatment of insomnia associated with Generalized Anxiety Disorder when used concomitantly with escitalopram</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To show that treating insomnia from beginning of SSRI (Selective Serotonin Reuptake Inhibitor) treatment for anxiety results in improvement in quality of life and possibly greater response to anti-anxiety therapy</measure>
  </secondary_outcome>
  <enrollment>372</enrollment>
  <condition>Insomnia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem tartrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Male or female between the ages of 21and 64 years, inclusive;&#xD;
&#xD;
          2. Women must use a medically acceptable form of contraception during the entire study&#xD;
             period, or: be surgically sterilized, post-menopausal, agree to use double-barrier&#xD;
             contraception throughout the study period, or must have a negative urine pregnancy&#xD;
             test prior to randomization;&#xD;
&#xD;
          3. Must meet the diagnostic requirements of Generalized Anxiety Disorder as defined by&#xD;
             the Diagnostic and Statistical Manual of Mental Disorders;&#xD;
&#xD;
          4. Score at least 18 on the Hamilton Rating Scale for Anxiety (HAM-A)&#xD;
&#xD;
          5. Must be either newly diagnosed or show symptoms of relapse during a period of no drug&#xD;
             therapy for anxiety.&#xD;
&#xD;
          6. Subject must experience sleep disturbances at least three nights per week, for at&#xD;
             least one month prior to study entry, based on historical data.&#xD;
&#xD;
          7. Subject must be stabilized on all long-term medication therapy for at least one month&#xD;
             prior to study entry.&#xD;
&#xD;
        EXCLUSION&#xD;
&#xD;
          1. History of Post-Traumatic Stress Disorder;&#xD;
&#xD;
          2. Concomitant Major Depressive Disorder or Bipolar Disorder;&#xD;
&#xD;
          3. Any abnormal pre-study laboratory values that require clinical intervention&#xD;
&#xD;
          4. Shift work or requirement for a regular change in sleep schedule by at least six hours&#xD;
             within the previous month.&#xD;
&#xD;
          5. Pregnant or breastfeeding&#xD;
&#xD;
          6. History of drug addiction, alcoholism, or drug abuse&#xD;
&#xD;
          7. Currently using a benzodiazepine or SSRI or more than 2 days of use within the 28 days&#xD;
             preceding randomization.&#xD;
&#xD;
          8. A positive urine drug screen for compounds that would interfere with the assessment of&#xD;
             a hypnotic.&#xD;
&#xD;
          9. Use of prescription and non-prescription sedative drugs;&#xD;
&#xD;
         10. Prior failure to respond to escitalopram therapy for anxiety&#xD;
&#xD;
         11. The presence of any untreated or uncompensated clinically significant renal,&#xD;
             endocrine, gastrointestinal, hepatic, respiratory, cardiovascular, other neurologic,&#xD;
             hematologic, oncologic, immunologic, cerebrovascular disease or malignancy.&#xD;
&#xD;
         12. History of sleep apnea&#xD;
&#xD;
         13. History of myasthenia gravis&#xD;
&#xD;
         14. Known hypersensitivity and/or allergy to or previous adverse experience with zolpidem&#xD;
             or escitalopram or any of their excipients&#xD;
&#xD;
         15. Subject is currently participating in another clinical trial (or within 28 days of&#xD;
             screening).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis Diener</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2006</study_first_posted>
  <last_update_submitted>October 11, 2007</last_update_submitted>
  <last_update_submitted_qc>October 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

